NVO

Peers: LLY AMGN PFE AZN SNY NVS MRK BMY ABBV JNJ

| Held by: PPH AVDE WCMI FENI PID AVIV RODM APIE OZEM AQEC

Index	-
Market Cap	134.84B
Enterprise Value	149.39B
Income	18.19B
Sales	51.45B
Book/sh	7.66
Cash/sh	2.06
Dividend Est.	1.74 (4.32%)
Dividend TTM	1.80 (4.46%)
Dividend Ex-Date	Aug 17, 2026
Dividend Gr. 3/5Y	26.98% 19.93%
Payout	36.87%
Employees	68794
IPO	Apr 30, 1981

P/E	9.85
Forward P/E	12.20
PEG	-
P/S	2.62
P/B	5.26
P/C	19.60
P/FCF	11.43
EV/EBITDA	5.63
EV/Sales	2.90
Quick Ratio	0.66
Current Ratio	0.87
Debt/Eq	0.63
LT Debt/Eq	0.55
Option/Short	Yes / Yes

EPS (ttm)	4.09
EPS next Y	3.30
EPS next Q	0.73
EPS this Y	-8.59%
EPS next Y	-0.68%
EPS next 5Y	-0.64%
EPS past 3/5Y	26.28% 20.36%
Sales past 3/5Y	23.19% 19.21%
EPS Y/Y TTM	12.68%
Sales Y/Y TTM	13.21%
EPS Q/Q	-18.69%
Sales Q/Q	4.59%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	24.09% 11.40%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	9.78%
Inst Trans	-0.42%
ROA	21.81%
ROE	60.35%
ROIC	34.67%
Gross Margin	80.65%
Oper. Margin	45.38%
Profit Margin	35.36%
SMA20	3.44%
SMA50	-1.64%
SMA200	-8.40%
Trades

Shs Outstand	3.35B
Shs Float	3.35B
Short Float	1.12%
Short Ratio	2.96
Short Interest	37.44M
52W High	64.16 -37.19%
52W Low	35.12 14.75%
Volatility	1.54% 1.67%
ATR (14)	0.79
RSI (14)	55.51
Beta	0.71
Rel Volume	0.79
Avg Volume	12.67M
Volume	935,343

Perf Week	4.22%
Perf Month	7.35%
Perf Quarter	-9.50%
Perf Half Y	-10.18%
Perf YTD	-20.79%
Perf Year	-17.94%
Perf 3Y	-58.95%
Perf 5Y	-30.25%
Perf 10Y	132.08%
Recom	3.00
Target Price	49.66
Prev Close	40.45
Price	40.30
Change %	-0.37%

Consensus

Hold

Avg. Price Target

$49.66

Implied Upside

+23.2%

Analysts14incl. previous ratings

Rating Distribution2 Buy · 9 Hold · 3 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 11, 2026	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$40	-0.7%
Aug 27, 2026	Downgrade	DDeutsche Bank	Hold → Sell
Aug 12, 2026	Downgrade	BBerenberg	Buy → Hold
Mar 26, 2026	Initiated	WWolfe Research	Peer Perform
Mar 18, 2026	Initiated	BBernstein	Underperform
Mar 18, 2026	Initiated	BBernstein	Outperform	$175	+334.2%
Mar 10, 2026	Downgrade	TTD Cowen	Buy → Hold	$42	+4.2%
Mar 03, 2026	Upgrade	MMorgan Stanley	Underweight → Equal-Weight	$40	-0.7%
Mar 02, 2026	Downgrade	GGoldman	Buy → Neutral	$41	+1.7%
Feb 24, 2026	Downgrade	KKepler	Buy → Hold
Feb 24, 2026	Downgrade	JJP Morgan	Overweight → Neutral
Feb 23, 2026	Downgrade	DDeutsche Bank	Buy → Hold
Feb 12, 2026	Upgrade	JJefferies	Underperform → Hold
Jan 27, 2026	Initiated	CCitigroup	Neutral
Dec 08, 2025	Downgrade	AArgus	Buy → Hold
Oct 27, 2025	Resumed	JJefferies	Underperform
Oct 01, 2025	Upgrade	HHSBC Securities	Hold → Buy
Sep 29, 2025	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$47	+16.6%
Sep 17, 2025	Upgrade	BBerenberg	Hold → Buy
Sep 16, 2025	Upgrade	RRothschild & Co Redburn	Neutral → Buy

Nov-02-26 04:39PM	Earnings live updates: Roku posts earnings beat ahead of acquisition by Fox (Yahoo Finance)
Nov-01-26 10:52PM	Stocktwits Pharma Pulse: Biotech Beats The Broader Market Novo, Pfizer And Moderna Earnings Up Next (Stocktwits)
Oct-29-26 01:42PM	Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump (Reuters)
11:30AM	Novo Nordisk faces tougher GLP-1 competition, Citi says (Proactive)
Oct-28-26 02:23PM	Lillys retatrutide beats Ozempic in head-to-head trial (Clinical Trials Arena)
01:30PM	Loading…
01:30PM	Lilly's next-gen weight loss drug more than doubled Novo Nordisk's in trial (Quartz)
10:21AM	After Wegovy and Zepbound, 6 weight-loss drugs in development (Quartz)
08:35AM	LLY Vs NVO: Lillys Retatrutide Beats Novos Ozempic In Head-To-Head Trial Retatrutide More Than Doubles Weight Loss (Stocktwits)
Oct-27-26 02:21PM	Novo Nordisk Confronts Its Promised Second-Half Slowdown As Wegovy Pill Carries The Load (Earnings Whispers)
Oct-26-26 04:14PM	US judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk (Reuters)
10:57AM	Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? (FinanceWire)
Oct-23-26 05:59AM	GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says (Reuters)
03:14AM	Heineken document reveals worries over weight-loss drugs and beer sales (Reuters)
Oct-22-26 07:40AM	Laboratory operator Quest reports cyber breach affecting patient records (Reuters)
Oct-21-26 01:16PM	Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) (FinanceWire)
02:06AM	Loading…
02:06AM	Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market (Reuters)
12:01AM	Latest Wellness ETF Supplement: Peptides (The Daily Upside)
Oct-20-26 04:35PM	OpenAI acquires startup Orchestra Bio to beef up its biotech business (TechCrunch)
02:35PM	OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports (Investing.com)
09:30AM	Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis (Quartz)
Oct-18-26 09:30AM	European Union Regulators Recommend Approval For Eli Lilly Weight Loss Pill (TIKR)
Oct-16-26 11:29AM	Lillys Foundayo wins EMA panel backing for obesity and type 2 diabetes (Pharmaceutical Technology)
07:37AM	Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up (Reuters)
Oct-14-26 08:53AM	Vikings Key Obesity Pill Enters Phase 3 Trial Heres What Investors Need To Know (Stocktwits)
Oct-13-26 03:38PM	Top Analyst Reports for Walmart, Visa & Novo Nordisk (Zacks)
11:36AM	Walmart to cover GLP-1s, insulin at no cost for workers in benefits push - report (Investing.com)
Oct-09-26 09:12PM	Stocktwits Biotech Dealmaker Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights (Stocktwits)
06:52AM	Citi Cuts Novo Nordisk Price Target to DKK 296 on Limited Margin Growth Outlook (InvestorsHub)
02:36AM	Novo Nordisk stock target cut at Citi on lack of margin growth (Investing.com)
Oct-08-26 08:30AM	GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution (MarketWatch)
03:00PM	Loading…
Oct-07-26 03:00PM	Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock. (Barrons.com)
Oct-05-26 08:00AM	FDA Extends Review of Novo Nordisk Haemophilia A Treatment Denecimig (InvestorsHub)
Oct-02-26 08:13PM	Stocktwits Biotech Dealmaker Novartis, Sanofi And Novo Sign Weeks Biggest Deals (Stocktwits)
07:57PM	Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long (Stocktwits)
07:36PM	Anthropic Is Spending $100M To Build The AI Workforce It Needs For Its Next Phase (Stocktwits)
09:00AM	3 drug targets pharma is betting on next (Pharma Voice)
Oct-01-26 03:19PM	How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market (Barrons.com)
09:00AM	Eli Lilly obesity drug data adds pressure on Novo Nordisk (Proactive)
08:43AM	Novo Nordisk Reports Wegovy Liver Fat Reduction in Obesity Trial Analysis (InvestorsHub)
Sep-30-26 10:59AM	Eli Lilly stock rises on striking 23% weight loss in drug combo trial (Investing.com)
10:32AM	Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects. (MarketWatch)
08:32AM	Novo Nordisk Wegovy pill weight loss switch study results (Quartz)
08:32AM	Switching to Novo Nordisk's weight loss pill helped people keep shedding pounds (Quartz)
08:27AM	Novo Nordisk Study Reports Weight Loss After Patients Switch to Oral Wegovy (InvestorsHub)
Sep-29-26 02:16PM	Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy (GuruFocus.com)
12:10PM	Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge (GuruFocus.com)
11:57AM	Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data (GuruFocus.com)
08:36AM	Novo Nordisk Reports Real-World Semaglutide 2 mg Cardiovascular Analysis Versus Tirzepatide (InvestorsHub)
08:03AM	Taking Ozempic and worried about vision loss? This test can help you understand your risk. (MarketWatch)
05:45AM	Novo Nordisk strikes second licensing deal since frosty capital-markets day (MarketWatch)
01:46AM	Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal (Investing.com)
Sep-27-26 11:31PM	Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week Here Are The Stocks And Readouts To Watch (Stocktwits)
Sep-25-26 09:02PM	Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines (Stocktwits)
03:53PM	Viatris sues Novo Nordisk over generic Wegovy patent dispute (Investing.com)
10:05AM	Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem (GuruFocus.com)
09:56AM	Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech (GuruFocus.com)
09:50AM	Novo Nordisk signed a $1.3 billion deal for technology to make longer-lasting obesity shots (Quartz)
09:46AM	Novo Nordisk signs $1.3 billion deal for long-acting obesity shots (Quartz)
06:15AM	Novo Nordisk Licenses Nanexa Drug-Delivery Technology in Deal Worth Up to 1.17 Billion (InvestorsHub)
05:11AM	After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring (MarketWatch)
03:49AM	Nanexa shares rocket 114% on $1.3 billion Novo Nordisk licensing deal (Investing.com)
Sep-23-26 04:36PM	NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day Direct US Listing Talks, Drug Approval Fail To Halt Slip (Stocktwits)
03:24PM	Novo's Oral Wegovy Just Revealed a Surprising Weight-Loss Signal (GuruFocus.com)
12:12PM	Novo Nordisk open to direct New York listing, CEO says (Proactive)
11:09AM	Huge News For Novo Nordisk Fans (GuruFocus.com)
10:52AM	European big pharma unites amid ringing alarm bells of continents dominance (Clinical Trials Arena)
08:41AM	Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets (TIKR)
07:37AM	The Stock Market Is Sleeping on the Next Big AI Catalyst (Barrons.com)
07:09AM	U.S. demand for Novo Nordisks weight loss drugs is so huge that the Danish central bank just doubled the nations entire growth forecast (Fortune)
06:10AM	Novo Nordisk CEO Says Company Open to Direct NYSE Share Listing (InvestorsHub)
Sep-22-26 10:22PM	VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data Can Viking Win Over Wegovy And Zepbound Users? (Stocktwits)
05:24PM	Novo Nordisk Just Made a Surprising Move Beyond Weight Loss (GuruFocus.com)
04:31PM	VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win (Stocktwits)
03:26PM	AstraZeneca and GSK warn Europes drug industry is at risk (The Telegraph)
02:51PM	Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch (Barrons.com)
09:49AM	Viking Therapeutics Stock Surges on Drug Trial Success (Schaeffer's Research)
09:42AM	Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial (InvestorsHub)
08:22AM	Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire. (Barrons.com)
08:08AM	VKTX Stock Spikes 38% Premarket: Vikings VK2735 Shows Promise For Weight-Loss Maintenance (Stocktwits)
07:29AM	GLP-1 maker Novo Nordisk's big reveal leaves the City cold (Proactive)
06:45AM	Novo Nordisk Considers Acquisitions to Expand Weight-Loss Drug Pipeline as Competition Intensifies (InvestorsHub)
01:29AM	VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
Sep-21-26 03:49PM	LLY Stock Gains As CEO Says Foundayo Wins One-Third Of New GLP-1 Pill Starts, Breaks Ground On $6.5B Houston Plant (Stocktwits) -7.96%
03:09PM	Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round (GuruFocus.com)
11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
10:46AM	Novo Shares Slip as Growth Plan Disappoints Investors (Schaeffer's Research)
08:35AM	Novo Nordisk's $23B Obesity Goal Isn't Enough to Stop the Selloff (GuruFocus.com)
08:29AM	Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan (Barrons.com)
08:26AM	Novo Nordisk Shares Sink After $23 Billion Obesity Sales Target for 2030 (GuruFocus.com)
08:20AM	Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers (GuruFocus.com)
07:31AM	Novo Nordisk Targets Over Five New Blockbusters By 2030, But NVO Stock Slides On Growth Concerns (Stocktwits)
07:20AM	Novo Nordisk stock sinks after 2030 growth plan fails to impress investors (Quartz)
07:19AM	Novo Nordisk stock falls after 2030 strategy disappoints investors (Quartz)
07:13AM	Paramount shares climb on report of negotiations, and other early market movers (MarketWatch)
06:30AM	Novo Nordisk Shares Fall 6% as Drugmaker Outlines Growth Targets Through 2030 (InvestorsHub)
05:19AM	Novo Nordisk stock gets drilled on pipeline concerns its CEO sees this as the main problem (Yahoo Finance)
04:58AM	Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals (MarketWatch)
03:37AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to climb as oil prices fall following U.S. statement that shipments through Hormuz at six-month high (MarketWatch)
12:37AM	Biotech Week Ahead: XLV Beats The Market Here Are The Stocks, Readouts And Events To Watch Next (Stocktwits)
Sep-19-26 10:30PM	What does the EU have that the U.S. does not? (Investing.com)

Show Previous News

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Executive VPMr. Karsten Munk Knudsen

PresidentMr. Maziar Mike Doustdar B.A.

EVP of R&DDr. Martin Holst Lange

EVP of PeopleMs. Tania Sabroe

Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novo Nordisk ADR

Upgrade your Finviz experience